Ketorolac TromethamineThird Party Manufacturing in India

Ketorolac Tromethamine works by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which are responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are key mediators of pain, inflammation, and fever. By blocking both COX isoforms, Ketorolac reduces the synthesis of prostaglandins at the site of tissue injury, thereby decreasing pain perception and inflammatory response. Unlike opioid analgesics, Ketorolac achieves its analgesic effect through peripheral anti-inflammatory action rather than central nervous system opioid receptor binding. It is one of the most potent non-opioid analgesics available, with efficacy comparable to morphine in the management of moderate to severe acute pain. Ketorolac differs from other NSAIDs in that it is approved for short-term use (up to 5 days) due to its potent analgesic properties and potential for gastrointestinal and renal adverse effects with prolonged therapy. The tromethamine salt formulation enhances the drug's aqueous solubility, allowing for rapid absorption and faster onset of action.

Therapeutic Uses

Ketorolac Tromethamine is prescribed for the treatment of:

• Acute Postoperative Pain: Short-term management of moderate to severe pain following surgical procedures, including orthopaedic, abdominal, and gynaecological surgery.
• Ocular Inflammation: Post-operative inflammation following cataract extraction and corneal refractive surgery, available as ophthalmic solution.
• Acute Musculoskeletal Pain: Severe acute back pain, dental pain, and soft tissue injuries requiring potent analgesia.
• Renal Colic: Management of pain associated with kidney stones in emergency settings.

Why Manufacturers Choose Ketorolac Tromethamine

Ketorolac Tromethamine occupies a unique position in the analgesic market as the only injectable NSAID with opioid-level analgesic efficacy. It is a hospital-use mainstay in anaesthesia and emergency medicine departments worldwide. Indian manufacturers produce both tablet and injectable forms for domestic and export markets, with the ophthalmic formulation representing a high-value niche. The molecule's established safety profile and well-documented clinical data make regulatory approvals straightforward in most markets. For PCD franchise operators, Ketorolac tablets and injections generate consistent repeat orders from hospitals and nursing homes.

This makes Ketorolac Tromethamine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.